Skip to main content

Table 4 MGMT promoter methylation status and progress and survival of patients. Promoter methylation was determined by HRM, MSP, and PSQ

From: MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

Promoter status

HRM

MSP

PSQ

Methylated MGMT promoter

 Progression-free survival

  Median duration (months)

6.0 (3.64–8.36)

4.4 (3.09–5.72)

4.6 (2.88–6.32)

  Rate at 6 months (%)

51.9

40.0

46.7

 Overall survival

  Median duration (months)

14.0 (6.50–21.50)

11.0 (8.19–13.81)

11.0 (0.27–21.74)

  Rate at 18 months (%)

48.1

40.0

46.7

Unmethylated MGMT promoter

 Progression-free survival

  Median duration (months)

4.0 (3.80–4.20)

4.2 (3.67–4.73)

4.0 (3.67–4.33)

  Rate at 6 months (%)

31.6

40.0

34.3

 Overall survival

  Median duration (months)

10.0 (5.03–14.97)

12.0 (7.36–16.64)

11.0 (7.62–14.38)

  Rate at 18 months (%)

23.7

31.1

22.9

  1. Numbers in parentheses are 95 % confidence intervals